ATE405286T1 - Neue mittel zur linderung von motorischen störungen - Google Patents

Neue mittel zur linderung von motorischen störungen

Info

Publication number
ATE405286T1
ATE405286T1 AT01961246T AT01961246T ATE405286T1 AT E405286 T1 ATE405286 T1 AT E405286T1 AT 01961246 T AT01961246 T AT 01961246T AT 01961246 T AT01961246 T AT 01961246T AT E405286 T1 ATE405286 T1 AT E405286T1
Authority
AT
Austria
Prior art keywords
new means
motor disorders
relieving
treating neurodegenerative
neurodegenerative diseases
Prior art date
Application number
AT01961246T
Other languages
English (en)
Inventor
Masaki Hirashima
Takumi Sasaki
Takeshi Naruse
Hiroaki Maeda
Chikateru Nozaki
Original Assignee
Chemo Sero Therapeut Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeut Res Inst filed Critical Chemo Sero Therapeut Res Inst
Application granted granted Critical
Publication of ATE405286T1 publication Critical patent/ATE405286T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Vehicle Body Suspensions (AREA)
  • Paper (AREA)
AT01961246T 2001-03-23 2001-08-31 Neue mittel zur linderung von motorischen störungen ATE405286T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001084050 2001-03-23

Publications (1)

Publication Number Publication Date
ATE405286T1 true ATE405286T1 (de) 2008-09-15

Family

ID=18939780

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01961246T ATE405286T1 (de) 2001-03-23 2001-08-31 Neue mittel zur linderung von motorischen störungen

Country Status (8)

Country Link
US (2) US20050037954A1 (de)
EP (1) EP1374887B1 (de)
JP (1) JPWO2002076492A1 (de)
AT (1) ATE405286T1 (de)
AU (1) AU2010251788B2 (de)
CA (1) CA2441403A1 (de)
DE (1) DE60135501D1 (de)
WO (1) WO2002076492A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1393740A4 (de) * 2001-05-11 2005-08-10 Juridical Foundation Neue mittel zur behandlung neurodegenerativer erkrankungen
JP4226909B2 (ja) * 2001-05-11 2009-02-18 財団法人化学及血清療法研究所 細胞障害抑制活性を有するペプチドおよび当該細胞障害抑制活性を有するペプチドのスクリーニング方法
JP2004182616A (ja) * 2002-11-29 2004-07-02 Chemo Sero Therapeut Res Inst 新規な神経伝達機能異常疾患改善剤
US8754084B2 (en) 2012-03-27 2014-06-17 The Board Of Trustees Of The University Of Illinois Therapeutic methods and agents for treating myotonic dystrophy
US9376421B2 (en) 2014-08-08 2016-06-28 The Board Of Trustees Of The University Of Illinois Compounds and methods for myotonic dystrophy therapy
CN107405382A (zh) 2015-02-06 2017-11-28 加利福尼亚大学董事会 用于改善认知的方法和组合物
US11078236B2 (en) 2017-05-02 2021-08-03 Burke Neurological Institute Selenium-based therapies
US11242326B2 (en) 2017-08-25 2022-02-08 The Board Of Trustees Of The University Of Illinois Multivalent ligand for myotonic dystrophy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977244A (en) * 1985-06-27 1990-12-11 The United States Of America As Represented By The Department Of Health And Human Services Uromodulin and a process of purifying it
AT397200B (de) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung von selenmethionin zur herstellung eines arzneimittels
ATE432287T1 (de) 1998-11-19 2009-06-15 Chemo Sero Therapeut Res Inst Peptidfragmente mit den zelltod verhindernder aktivität
EP1393740A4 (de) 2001-05-11 2005-08-10 Juridical Foundation Neue mittel zur behandlung neurodegenerativer erkrankungen
JP4226909B2 (ja) 2001-05-11 2009-02-18 財団法人化学及血清療法研究所 細胞障害抑制活性を有するペプチドおよび当該細胞障害抑制活性を有するペプチドのスクリーニング方法

Also Published As

Publication number Publication date
EP1374887A4 (de) 2004-07-07
DE60135501D1 (de) 2008-10-02
EP1374887A1 (de) 2004-01-02
AU2010251788B2 (en) 2011-05-19
US20050037954A1 (en) 2005-02-17
US20090075865A1 (en) 2009-03-19
EP1374887B1 (de) 2008-08-20
AU2010251788A1 (en) 2011-01-06
CA2441403A1 (en) 2002-10-03
US7704951B2 (en) 2010-04-27
JPWO2002076492A1 (ja) 2004-07-15
WO2002076492A1 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
DE602004021797D1 (de) Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie
ATE451929T1 (de) Von casein abgeleitete peptide und deren anwendung für die therapie
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
NZ263344A (en) Human bactericidal/permeability increasing (bpi) protein functional domain peptides and their use
DE69526216D1 (de) Antifungaleverfahren und mitteln
ATE312909T1 (de) Diagnostika und behandlungen von peridontalen erkrankungen
ATE280777T1 (de) Bradykinin-antagonist peptide mit n- substituierten glycinen
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
ATE405286T1 (de) Neue mittel zur linderung von motorischen störungen
DE69821793D1 (de) Neuronale verwendungen des bmp-11
ATE410139T1 (de) Kosmetische zusammensetzung auf basis von zink- und kupfersulfaten und sucralphat
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
EA200601238A1 (ru) Медикаменты для профилактики и лечения бромидроза и для улучшения запаха тела
ATE455553T1 (de) Verwendung von hsp20 zur förderung der wundheilung und/oder zur reduzierung der narbenbildung
PT938329E (pt) Composicao de tlp imunogenica
DE60223564D1 (de) Therapeutische impfzusammensetzung zur verhütung und behandlung von erkrankungen bei säugetieren
EP1566386A4 (de) Gen in zusammenhang mit haarausfall, das davon kodierte polypeptid und anwendungen dafür
WO2002088380A3 (en) Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof
WO2002000828A3 (fr) Nouveau polypeptide, proteine a doigt de zinc 34, et polynucleotide codant ce polypeptide
ATE247467T1 (de) Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin
WO2001083685A3 (fr) Nouveau polypeptide, proteine cap 10, et polynucleotide codant pour ce polypeptide
WO2001046243A3 (fr) Nouveau polypeptide, proteine annulaire 8, et polynucleotide codant pour ce polypeptide
WO2001075020A3 (fr) Nouveau polypeptide, neuroproteine humaine y 11, et polynucleotide codant pour ce polypeptide
WO2001079439A3 (fr) Nouveau polypeptide, proteine humaine de reception cannabinoide 19, et un polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties